Clinical Trial Update: A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis [Phase 1]

View source ↗

Summary

Phase 1 study update on KYV-101, a CD19 CAR T cell therapy, for treatment-refractory Progressive Multiple Sclerosis, with the trial currently active but not rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Multiple Sclerosis

Drugs mentioned

• KYV-101

Snippet

Sponsor: Bruce Cree | Conditions: Progressive Multiple Sclerosis | Phase 1 | Status: ACTIVE_NOT_RECRUITING